Table 1. Baseline Characteristics (N = 20).
| Characteristic | |
|---|---|
| Median Age, Range | 62 (50-83) |
| Male/Female | 16/4 |
| ECOG Performance Status (0/1) | 13/7 |
| *MSKCC Prognostic Groups | |
| Favorable | 4 |
| Intermediate | 15 |
| Poor | 1 |
| Histology | |
| Clear cell | 17 |
| Papillary | 2 |
| Mixed or unclassified | 1 |
| Prior Nephrectomy | 15 |
| Previous Therapy History | |
| Systemic chemotherapy | 5 |
| Immunotherapy | 9 |
| Antiangiogenic treatment | 12 |
| Median Number (Range) of Previous Therapies | 2 (1-3) |
*
MSKCC Prognostic Groups for previously treated metastatic RCC: 1 point for each of the following factors: Kornafsky performance status < 80%, corrected calcium < 10 mg/dL, and hemoglobin < 13 g/dL for males and < 11.5 g/dL for females. Risk stratification: good - 0 risk factors; intermediate - 1 risk factor; poor - 2 or 3 risk factors.24
Abbreviations: ECOG = Eastern Cooperative Oncology Group; MSKCC = Memorial Sloan-Kettering Cancer Center